PTAB institutes IPRs of Bass' Gattex petitions
The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office instituted two inter partes review (IPR) petitions from Kyle Bass' Coalition for Affordable Drugs challenging patents covering Gattex teduglutide from Shire plc (LSE:SHP; NASDAQ:SHPG). The two petitions separately challenged different claims of U.S. Patent No. 7,056,886, which describes stabilized formulations of glucagon-like peptide-2 ( GLP-2).
In one IPR challenge, PTAB found that prior art describing the stabilization of other protein formulations was sufficient for a person of ordinary skill to apply the same techniques to GLP-2. In a second petition, the board instituted review of some claims and rejected others. It found GLP-2 formulations that included specific buffering agents were obvious in prior art, but formulations with specific degradation rates were not. ...